Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia
This article was originally published in PharmAsia News
Executive Summary
Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.
You may also be interested in...
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.
Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives
An Anglo-Russian company, Pro Bono Bio, launches new analgesic and will price its products according to ability to pay.
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 Million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets